Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:4040809rdf:typepubmed:Citationlld:pubmed
pubmed-article:4040809lifeskim:mentionsumls-concept:C0029921lld:lifeskim
pubmed-article:4040809lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:4040809lifeskim:mentionsumls-concept:C1335703lld:lifeskim
pubmed-article:4040809lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:4040809lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:4040809lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:4040809lifeskim:mentionsumls-concept:C0086960lld:lifeskim
pubmed-article:4040809lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:4040809pubmed:issue9lld:pubmed
pubmed-article:4040809pubmed:dateCreated1985-10-15lld:pubmed
pubmed-article:4040809pubmed:abstractTextThirty patients with squamous cell carcinoma of the head and neck were treated with a combination of cisplatin (20 mg/m2) and 5-FU (400-200 mg/m2) by iv push on Days 1-5 every 21 days. All patients but two had relapsed disease. Twenty-seven patients were evaluable for response: there were four complete responses and 12 partial responses (objective response rate, 59.2%). The response rate falls to 53.3% if it is calculated on the total number of patients entered. Twenty-seven patients were evaluable for toxicity: myelosuppression occurred in ten patients (37%), while renal toxicity, nausea and vomiting, and stomatitis were quite rare and moderate. These results look encouraging and suggest the need for further studies.lld:pubmed
pubmed-article:4040809pubmed:languageenglld:pubmed
pubmed-article:4040809pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4040809pubmed:citationSubsetIMlld:pubmed
pubmed-article:4040809pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4040809pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4040809pubmed:statusMEDLINElld:pubmed
pubmed-article:4040809pubmed:monthSeplld:pubmed
pubmed-article:4040809pubmed:issn0361-5960lld:pubmed
pubmed-article:4040809pubmed:authorpubmed-author:RossiLLlld:pubmed
pubmed-article:4040809pubmed:authorpubmed-author:GrimaldiAAlld:pubmed
pubmed-article:4040809pubmed:authorpubmed-author:MargarinoGGlld:pubmed
pubmed-article:4040809pubmed:authorpubmed-author:MerlanoMMlld:pubmed
pubmed-article:4040809pubmed:authorpubmed-author:TatarekRRlld:pubmed
pubmed-article:4040809pubmed:issnTypePrintlld:pubmed
pubmed-article:4040809pubmed:volume69lld:pubmed
pubmed-article:4040809pubmed:ownerNLMlld:pubmed
pubmed-article:4040809pubmed:authorsCompleteYlld:pubmed
pubmed-article:4040809pubmed:pagination961-4lld:pubmed
pubmed-article:4040809pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:meshHeadingpubmed-meshheading:4040809-...lld:pubmed
pubmed-article:4040809pubmed:year1985lld:pubmed
pubmed-article:4040809pubmed:articleTitlePhase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.lld:pubmed
pubmed-article:4040809pubmed:publicationTypeJournal Articlelld:pubmed